Lucid files for 1-for-10 reverse stock split requiring shareholder approval
Investing.com - Heron Therapeuti (NASDAQ: HRTX) reported fourth quarter EPS of $0.020, $0.05 better than the analyst estimate of $-0.030. Revenue for the quarter came in at $40.78M versus the consensus estimate of $37.3M.
Guidance
Heron Therapeuti sees Q1 2025 revenue of $153.000M-$163.000M versus the analyst consensus of $160.600M.
Heron Therapeuti’s stock price closed at $1.71. It is up 43.700% in the last 3 months and down -36.670% in the last 12 months.
Heron Therapeuti saw 1 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Heron Therapeuti’s stock price’s past reactions to earnings here.
According to InvestingPro, Heron Therapeuti’s Financial Health score is "good performance".
Check out Heron Therapeuti’s recent earnings performance, and Heron Therapeuti’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar